BRACCO

LIFE FROM INSIDE

Sustainability at the core of our **growth**

Vueway®
(gadopiclenol) injection
485.1 mg/mL

An enhanced MRI experience with reduced gadolinium

Scan me
to view a video on how **Vueway®** can boost your sustainability.

Sustainability product factsheet

Vueway®: Reduced Gadolinium, Enhanced MRI Experience

Bracco's Vueway® delivers effective enhancement at half gadolinium dosing due to its high relaxivity, enhancing the MRI experience and driving more conscientious consumption of gadolinium

Benefits for providers and patients

Effective imaging with less gadolinium



Vueway® allows efficient enhancement at a

50%

lower gadolinium dose vs recommended dose of other macrocyclic GBCAs...[1]

...which facilitates **ALARA principle** application in day-to-day clinical practice

Benefits for the planet

Gadolinium management

In Europe, 19 tonnes of gadolinium are administered to patients every year; Vueway®'s lower dosing may **reduce gadolinium use by up to 50%**, potentially conserving 9,5 tonnes per year without compromising contrast enhancement.[2]



References:
[1] Loevner LA, et al. Invest Radiol 2023;58: 307–313.
[2] Brünjes R, Hofmann T. Water Research 2020;182:115966.

Before use of a product, please refer to locally approved SmPC which will be made available on request.

Sustainability at Bracco

We believe that looking after the planet and people is not just our responsibility but an opportunity to generate value for our customers, partners and our business.

We're putting sustainability at the core of our growth. That means minimising the environmental impact of our products across their life cycle; investing in the skills and knowledge of healthcare professionals and looking after our employees and our communities; and upholding the highest standards of governance in everything we do.

Bracco Imaging has earned its first **EcoVadis Platinum Medal**, ranking among **the top 1% of the world's most sustainable companies.**

100,000

Healthcare Professionals reached through educational activities worldwide in 2024

70% less CO_2e (CO_2 equivalent)*

Emissions reduction in Bracco operations through implemented or approved actions by 2030 (on 2014 baseline)

Carbon neutral commitment

We are committed to carbon neutrality in our own operations by 2030

-36% waste to landfill

The drop in the amount of waste we sent to landfill in 2024 vs. 2023

Data sourced from the 2024 Sustainability Full Report.

*CO_2e or CO_2 equivalent is the unit of measurement for the impact of greenhouse gases (GHGs) on global warming in terms of the amount of CO_2 calculated on the basis of the Global Warming Potential index

VUEWAY - ABBREVIATED SPC
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Detailed information on this medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu. 1.NAME OF THE MEDICINAL PRODUCT. Vueway 0.5 mmol/mL solution for injection. 2.QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 mL of solution contains 485.1 mg gadopiclenol (equivalent to 0.5 mmol of gadopiclenol and to 78.6 mg of gadolinium). 3.PHARMACEUTICAL form. Clear, colourless to pale yellow solution. 4.CLINICAL PARTICULARS. Therapeutic indications. Diagnostic use only. Indicated in adults and children aged 2 years and older, for contrast-enhanced magnetic resonance imaging (MRI) for: the brain, spine, and associated tissues of the central nervous system (CNS); the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system. It should be used only when diagnostic information is essential and not available with unenhanced MRI. 4.2 Posology and method of administration. 0.1 mL/kg body weight (BW) (equivalent to 0.05 mmol/kg BW) (Paediatric population (2 years and older) included). More than one dose should not be used during a scan. No adjustment needed for elderly, hepatic, or renal impairment. Caution in patients with severe renal impairment (GFR < 30 mL/min/1.73 m2) and in patients in the perioperative liver transplantation period. Use only if essential and if non-contrast enhanced MRI not available. Interval between injections needs to be at least 7 days. Method of administration: intravenous use only,as a bolus injection. Since experience shows that most undesirable effects occur within minutes after administration, the patient should be kept under observation during and following administration for at least half an hour. 4.4 Special warnings and precautions for use. Gadopiclenol must not be used intrathecally. Serious, life-threatening and fatal cases, primarily with neurological reactions (e.g. coma, encephalopathy, seizures), have been reported with intrathecal use of gadolinium-based contrast agents.Usual precautions such as exclusion of patients with pacemakers, ferromagnetic vascular clips, infusion pumps, nerve stimulators, cochlear implants, or suspected intracorporal metallic foreign bodies, particularly in the eye. Potential for hypersensitivity or anaphylactic reactions: higher in patients with a history of previous reaction to gadolinium-containing contrast agents, bronchial asthma or allergy. Renal impairment and nephrogenic systemic fibrosis (NSF): patients undergoing liver transplantation are at particular risk. Elderly: As the renal clearance of gadopiclenol may be impaired in the elderly, it is particularly important to screen patients aged 65 years and older for renal dysfunction. Caution should be exercised in patients with renal impairment. Seizures: special caution in patients with a lowered threshold for seizures. Extravasation: In case of extravasation, the injection must be stopped immediately. Cardiovascular disease: in patients with severe cardiovascular disease, only after careful risk benefit assessment. 4.5 Interaction with other medicinal products and other forms of interaction. No interaction studies performed. Beta-blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists decrease the efficacy of the mechanisms of cardiovascular compensation for blood pressure disorders. 4.6 Fertility, pregnancy and lactation. Pregnancy: Vueway should not be used during pregnancy unless the clinical condition of the woman requires use of gadopiclenol. Breast-feeding: Gadolinium-containing contrast agents are excreted into breast milk in very small amounts. Continuing or discontinuing breast feeding for a period of 24 hours after administration of Vueway, should be at the discretion of the doctor and breast-feeding mother. 4.8 Undesirable effects. The most frequent adverse reactions were injection site pain, headache, nausea, injection site coldness, fatigue and diarrhoea. Hypersensitivity: Immediate reactions include one or more effects, which appear simultaneously or sequentially, which are most often cutaneous, respiratory and/or vascular reactions. Each sign may be a warning sign of a starting shock and go very rarely to death. See full SmPC for details. Reporting of suspected adverse reactions: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. 4.9 Overdose. The maximum daily single dose tested in humans was 0.6 mL/kg BW (equivalent to 0.3 mmol/kg BW). See full SmPC for details. 5.1 Pharmacodynamic properties. ATC code: V08CA12. Gadopiclenol is a paramagnetic agent for Magnetic Resonance Imaging (MRI). 6.3Shelf life. 3 years. 6.4Special precautions for storage. For vials: any special storage conditions. For pre-filled syringes: Do not freeze. 7.MARKETING AUTHORISATION HOLDER. Bracco Imaging SPA-Via Egidio Folli, 50. 20134 Milan, Italy. 8.MARKETING AUTHORISATION NUMBER(S). EU/1/23/1773/001-025. 10.DATE OF REVISION OF THE TEXT. 12 December 2024